全球领先疫苗,39支疫苗进入3期实验,10月13日,德国法国放弃两款mRNA疫苗,转为研发新一代疫苗和加强剂。中国两款疫苗进入第三期试验。

1608181824463.png

New additions and recent updates
Dec. 16Russia’s Vector Institute moves to Phase 3.

PHASE 3 EARLY USE IN RUSSIA
Vector Institute logo

On Aug. 26, the Vector Institute, a Russian biological research center, registered a Phase 1/2 trial for a coronavirus vaccine they call EpiVacCorona. The vaccine contains small portions of viral proteins, known as peptides. According to newspaper reports, the EpiVacCorona trials had already begun by then.

On Oct. 14, Vladimir Putin announced that Russia has granted regulatory approval to the vaccine, making it the second one to receive that designation after the Gamaleya Institute’s Sputnik V vaccine. A Phase 3 trial began in November, and as of Dec. 15, the Interfax News Agency reported that 1,438 volunteers had received the vaccine.

Updated Dec. 15

今天俄国一款Protein subunit 疫苗进入三期试验,这款疫苗在一期试验时已获得早期使用批准。​


加拿大的疫苗追踪:
BCBDB7F0-1280-4810-A68B-B240C6C6371E.jpeg
 
最后编辑:
1608413079546.png

PHASE 2 PHASE 3 COMBINED PHASES

Clover Biopharmaceuticals
has developed a vaccine containing the spike protein from coronaviruses. To further stimulate the immune system, the company is testing so-called adjuvants made by British drugmaker GSK and the American company Dynavax. Investments from CEPI will support the development of manufacturing that could lead to the production of a billion doses a year. Clover’s formula looks to be especially durable; the vaccine can sit out at room temperature for a month and remain viable.

Clover launched a Phase 1 trial in June, and in December they announced that the vaccine triggered a high level of antibodies. The announcement was followed by the start of a The company is following up on the promising results by launching a Phase 2/3 trial with the GSK adjuvant. by the end of 2020.

总部位于四川的三叶草生物制药公司的疫苗,今天进入第二三期合并试验。第一期试验效果很好,公司正在测试由英国的GSK和美国的Dynavax生产的佐剂。

Updated Dec. 17

1608413005510.png

 
最后编辑:

阿联酋政府大规模向国民供应中国疫苗(组图)​



在美、英等国为第一批疫苗的分配问题而头疼时,阿拉伯联合酋长国已在6个酋长国,为全体成年居民提供免费的新冠疫苗,接种的正是本月初在该国获批的中国疫苗。

中国国药集团中国生物北京生物制品研究所(下简称:国药中生)研发的新冠病毒灭活疫苗,于今年9月,就在该国开展临床试验。本月初,国药中生疫苗在该国获批上市,系全球首次。

根据英国《金融时报》(FT)12月22日报道,目前,阿联酋国内的公、私立诊所、野战医院,都可以免费接种国药中生的新冠疫苗。“在其他国家按照年龄和易感性分配疫苗时,阿联酋将疫苗可及性拓展到全体成年人,包括100万国民和超800万外国居民。”
 

昨天哈萨克斯坦的灭活疫苗进入3期试验。​


PHASE 3

The central Asian nation of Kazakhstan began research on a vaccine made from inactivated coronaviruses over the summer. On August 28, their Research Institute for Biological Safety Problems registered a Phase 1 trial on the vaccine, known as QazCovid. On Dec. 19, Kazinform reported that Phase 2 had been completed, showing that the vaccine was safe and produced a promising immune response. The researchers commenced the Phase 3 trial, anticipating approval by March.

Updated Dec. 27

1609184723813.png
1609184740572.png


 

阿联酋政府大规模向国民供应中国疫苗(组图)​



在美、英等国为第一批疫苗的分配问题而头疼时,阿拉伯联合酋长国已在6个酋长国,为全体成年居民提供免费的新冠疫苗,接种的正是本月初在该国获批的中国疫苗。

中国国药集团中国生物北京生物制品研究所(下简称:国药中生)研发的新冠病毒灭活疫苗,于今年9月,就在该国开展临床试验。本月初,国药中生疫苗在该国获批上市,系全球首次。

根据英国《金融时报》(FT)12月22日报道,目前,阿联酋国内的公、私立诊所、野战医院,都可以免费接种国药中生的新冠疫苗。“在其他国家按照年龄和易感性分配疫苗时,阿联酋将疫苗可及性拓展到全体成年人,包括100万国民和超800万外国居民。”
但迪拜酋长也买了Pfizer的在给民众接种,可能是这个酋长国比较有钱吧
 
中国康希诺的疫苗已经在中国完成了一期和二期临床试验。六月份出二期评估报告。因为中国现在的病例很少,三期临床试验可能要和加拿大合作。一旦试验成功,我们就和中国同步取得疫苗。
估计cfc上有些人肯定是拒用中国疫苗的。有毒
陈薇这个骗子的东西估计没习了 (尽管在给军方医护人员施打),
她的AD5疫苗中和抗体滴度最低,要是在国内三期临床能有50-60%的有效了不起,因为国人至少一半有AD5抗体预存
 
英国药物及保健产品管理局(MHRA)30日批准牛津疫苗,是英国批准使用的第二个新冠疫苗。
英国卫生大臣韩考克30日说,牛津疫苗的批准是对抗新冠病毒一个「非常重要的时刻」,并称该疫苗的批准,将使英国「在春季前」摆脱疫情。


 
7 hr 13 min ago

UK is the first country to approve AstraZeneca's vaccine. Developing nations may benefit most from it​

From CNN's Mick Krever and Emma Reynolds

AstraZeneca has promised to supply hundreds of millions of doses of its Covid-19 vaccine to low and middle-income countries, and to deliver it on a not-for-profit basis to those nations in perpetuity.
The vaccine, developed at England's Oxford University, was approved for use by UK regulators on Wednesday -- the first country to do so.

It is significantly cheaper than other coronavirus vaccines and, crucially, it would be far easier to transport and distribute in developing countries than its rivals since it does not need to be stored at freezing temperatures.

"I think it's the only vaccine that can be used in those settings at the current time," Azra Ghani, chair in infectious disease epidemiology at Imperial College London, told CNN.

The Oxford/AstraZeneca vaccine can be kept at refrigerator temperatures of 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) for at least six months. Moderna's vaccine has to be stored at minus 20 degrees Celsius (minus 4 degrees Fahrenheit) -- or at refrigerator temperatures for up to 30 days -- and the Pfizer/BioNTech vaccine has to be stored at minus 75 degrees Celsius (minus 103 degrees Fahrenheit), and used within five days once refrigerated at higher temperatures.

"Pfizer and Moderna require freezer storage, and that just isn't in place in many settings," Ghani said.

"Cold chain" refrigeration is the standard storage used globally to deliver vaccines from central locations to local health clinics.

AstraZeneca's vaccine is so far "the only one that can definitely be delivered to those systems," Ghani added.

The vaccines are based on different technology. AstraZeneca's offering -- like Johnson & Johnson's vaccine and Russia's Sputnik V -- uses an adenovirus to carry genetic fragments of coronavirus into the body.

Read more:
UK regulator approves Oxford/AstraZeneca coronavirus vaccine
RELATED

UK regulator approves Oxford/AstraZeneca coronavirus vaccine

 
英国剑桥大学和AstraZeneca制药公司联合研制的COVID-19病毒肺炎疫苗被认为是到目前为止最容易使用的新冠病毒疫苗。其最实用的三个特点第一是成本低,每支疫苗售价2.5美元;第二是只需普通冰箱温度存储;第三是虽然也需要注射两次,但两次注射的间隔是三个月

这第三个特点意味着可以先给所有人注射完第一针疫苗后再开始第二轮注射;而不像辉瑞公司疫苗和莫德纳疫苗那样注射完第一针后要预留第二支疫苗用于在一个月内进行第二次注射。

https://www.rcinet.ca/zh/2020/12/30/英国刚批准的本国研制新冠疫苗更容易使用/
 
英国剑桥大学和AstraZeneca制药公司联合研制的COVID-19病毒肺炎疫苗被认为是到目前为止最容易使用的新冠病毒疫苗。其最实用的三个特点第一是成本低,每支疫苗售价2.5美元;第二是只需普通冰箱温度存储;第三是虽然也需要注射两次,但两次注射的间隔是三个月

这第三个特点意味着可以先给所有人注射完第一针疫苗后再开始第二轮注射;而不像辉瑞公司疫苗和莫德纳疫苗那样注射完第一针后要预留第二支疫苗用于在一个月内进行第二次注射。

https://www.rcinet.ca/zh/2020/12/30/英国刚批准的本国研制新冠疫苗更容易使用/
英国的这种方法可以使更多人注射第一针。

英国第一位打了辉瑞疫苗的91岁老人,今天注射第二针。
 
这个疫苗有一定优势,如果真像宣传中说的100%防住院率,应该比较好,然后再轻度感染一下,增强免疫。
如果选择,个人愿意打这个疫苗,毕竟mRNA第一次使用,有没有长期副作用还未知
 
这个疫苗还有个奇怪的地方,第一次打一半剂量,第二次打全剂量而且间隔3个月。
“LONDON — British health officials greenlighted the AstraZeneca and Oxford COVID-19 shot on Wednesday but also rebuffed one of their central claims: that a half-dose followed by a standard dose offered more protection against infection.”
是不是有可能第一次打一半剂量然后间隔3个月,是不是免疫的人轻度无症状感染自己产生的免疫,而不是疫苗产生的?
 

"While the exact cause of this kind of reaction isn't known, Carroll said dermatologists "try to apply what we know about fillers, what we know about vaccines and viruses and try to make a logical conclusion. So I think it would be an immune trigger. The vaccine is trying to target the immune system, trying to encourage the immune system toward that particular virus, but it's possible that it triggers other immune reactions within your body."

原因可能是激发了其他免疫反应,这个就需要研究,会不会让人对其他东西产生过敏反应
 
最后编辑:
后退
顶部